ProKidney reports Q4 net loss of $24.6M; cash $490.3M; Phase 3 trials advancing

PROKIDNEY CORP.

Cash and cash equivalents $490.3M as of Dec 31, 2022, vs $20.6M year-end 2021.
R&D expense $20.9M in Q4 2022, up from $10.7M in Q4 2021 due to clinical trial costs and hiring.
Net loss before noncontrolling interest $24.6M for Q4 2022, compared to $13.7M for Q4 2021.
Proact1 Phase 3 trial enrolling; interim data expected end of 2024; proact2 trial progressing toward initiation.
REACT received RMAT designation; EMA provided favorable scientific advice for Phase 3 program.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

PROKIDNEY CORP. reported the fourth quarter ended December 31, 2022 results: net income $24.6 million.

Period: the fourth quarter ended December 31, 2022
Net income: $24.6 million
Result: reported results

Exact text from the filing

Net loss before noncontrolling interest was $24.6 million and $13.7 million for the three months ended December 31, 2022, and 2021, respectively.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

PROKIDNEY CORP. reported financial results for the fiscal year ended December 31, 2022.

Period: the fiscal year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 28, 2023, ProKidney Corp. issued a press release to announce its financial results for the fourth quarter and fiscal year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

PROKIDNEY CORP. filing history →

Source: SEC EDGAR

accession 0000950170-23-010330

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.